Alexion expands Irish facility

A total of 400 direct and indirect jobs are being created by US niche drug firm, Alexion Pharmaceuticals as part of its second major Irish-based expansion announcement in as many months.

The Connecticut-headquartered firm — which works on treatments for people carrying ultra-rare and life-threatening disorders — yesterday announced the creation, within the next two years, of 200 full-time jobs via the building of its third facility here; a new €75m global supply chain facility at Blanchardstown, west Dublin.

Another 200 jobs are to be indirectly created through the construction of the new facility, which is due to open in 2016/17.